Research programme: cancer therapeutics - Supratek Pharma

Drug Profile

Research programme: cancer therapeutics - Supratek Pharma

Alternative Names: SP-1014C; SP-1030C; SP-1031C; SP-1063C

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Supratek Pharma
  • Class
  • Mechanism of Action Alkylating agents; DNA topoisomerase I inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Prostate cancer
  • No development reported Colorectal cancer; Haematological malignancies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in Canada (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in Canada (Parenteral)
  • 09 Oct 2015 Preclinical trials in Chronic lymphocytic leukaemia in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top